# Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants 

Source: https://onco.cc/trials/nct04975997/  
OnCo record `nct04975997` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dexamethasone, Daratumumab, Bortezomib in multiple myeloma, run by Celgene, active and no longer recruiting.

## Summary

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04975997 by Celgene, with 939 participants enrolled, started 2022-06-23 and due to reach its primary completion in 2027-11-16. Interventions recorded: Dexamethasone, Daratumumab, Bortezomib, Iberdomide, Iberdomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04975997
- Phase: 3
- Setting: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
- Sponsor: Celgene
- Enrolled: 939

## Sources

- ClinicalTrials.gov NCT04975997: https://clinicaltrials.gov/study/NCT04975997

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Bortezomib](https://onco.cc/drugs/bortezomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Iberdomide](https://onco.cc/drugs/iberdomide/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct04975997.json